JP2021501147A5 - - Google Patents

Info

Publication number
JP2021501147A5
JP2021501147A5 JP2020523284A JP2020523284A JP2021501147A5 JP 2021501147 A5 JP2021501147 A5 JP 2021501147A5 JP 2020523284 A JP2020523284 A JP 2020523284A JP 2020523284 A JP2020523284 A JP 2020523284A JP 2021501147 A5 JP2021501147 A5 JP 2021501147A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020523284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501147A (ja
JP7550643B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/057286 external-priority patent/WO2019084118A2/en
Publication of JP2021501147A publication Critical patent/JP2021501147A/ja
Priority to JP2023018374A priority Critical patent/JP7793562B2/ja
Publication of JP2021501147A5 publication Critical patent/JP2021501147A5/ja
Application granted granted Critical
Publication of JP7550643B2 publication Critical patent/JP7550643B2/ja
Priority to JP2025113783A priority patent/JP2025163031A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020523284A 2017-10-25 2018-10-24 リン酸化タウペプチドの組成物およびその使用 Active JP7550643B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023018374A JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用
JP2025113783A JP2025163031A (ja) 2017-10-25 2025-07-04 リン酸化タウペプチドの組成物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577157P 2017-10-25 2017-10-25
US62/577,157 2017-10-25
PCT/US2018/057286 WO2019084118A2 (en) 2017-10-25 2018-10-24 PHOSPHORYLATED TUBE PEPTIDE COMPOSITIONS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023018374A Division JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用

Publications (3)

Publication Number Publication Date
JP2021501147A JP2021501147A (ja) 2021-01-14
JP2021501147A5 true JP2021501147A5 (enExample) 2024-07-29
JP7550643B2 JP7550643B2 (ja) 2024-09-13

Family

ID=64362628

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020523284A Active JP7550643B2 (ja) 2017-10-25 2018-10-24 リン酸化タウペプチドの組成物およびその使用
JP2023018374A Active JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用
JP2025113783A Pending JP2025163031A (ja) 2017-10-25 2025-07-04 リン酸化タウペプチドの組成物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023018374A Active JP7793562B2 (ja) 2017-10-25 2023-02-09 リン酸化タウペプチドの組成物およびその使用
JP2025113783A Pending JP2025163031A (ja) 2017-10-25 2025-07-04 リン酸化タウペプチドの組成物およびその使用

Country Status (25)

Country Link
US (4) US11958889B2 (enExample)
EP (1) EP3700556A2 (enExample)
JP (3) JP7550643B2 (enExample)
KR (2) KR20240145065A (enExample)
CN (2) CN111787942B (enExample)
AR (1) AR113792A1 (enExample)
AU (2) AU2018355325B2 (enExample)
BR (1) BR112020008168A2 (enExample)
CA (2) CA3079423A1 (enExample)
CL (2) CL2020001070A1 (enExample)
CO (1) CO2020006073A2 (enExample)
CR (1) CR20240219A (enExample)
DO (1) DOP2020000135A (enExample)
EA (1) EA202091012A1 (enExample)
EC (1) ECSP20026986A (enExample)
IL (2) IL302108A (enExample)
JO (1) JOP20200103A1 (enExample)
MA (1) MA50465A (enExample)
MX (2) MX2020004338A (enExample)
MY (1) MY202233A (enExample)
PH (1) PH12020550432A1 (enExample)
SA (1) SA520411820B1 (enExample)
SG (1) SG11202003556UA (enExample)
TW (2) TW202333768A (enExample)
WO (1) WO2019084118A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111787942B (zh) 2017-10-25 2024-03-29 杨森制药公司 磷酸化Tau肽的组合物及其用途
US12365724B2 (en) * 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
MY206596A (en) 2019-02-08 2024-12-25 Janssen Pharmaceuticals Inc Method of safe administration of phosphorylated tau peptide vaccine
JOP20210284A1 (ar) * 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو
US20210128755A1 (en) * 2019-07-08 2021-05-06 Alzeca Biosciences, LLC Targeting ligands for tau pathology
WO2021056064A1 (en) * 2019-09-23 2021-04-01 Macquarie University Treatment of tauopathies
JP7829485B2 (ja) 2019-12-20 2026-03-13 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なＴｏｌｌ様受容体（「ＴＬＲ」）アゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
US20230131808A1 (en) * 2020-04-22 2023-04-27 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof
EP4212172A4 (en) * 2020-09-08 2024-10-16 Osaka University Immunogenic composition targeting phosphorylated tau protein
JP2023541671A (ja) * 2020-09-17 2023-10-03 プロシーナ バイオサイエンシーズ リミテッド シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン
CA3228878A1 (en) * 2021-08-12 2023-02-16 Andrea Pfeifer Liposomes containing phosphorylated tau peptides for inducing sustained immune responses
JP2024538615A (ja) * 2021-09-29 2024-10-23 ヤンセン ファーマシューティカルズ，インコーポレーテッド タウホスホペプチドコンジュゲートの安全な投与の方法
KR20240147981A (ko) * 2022-02-09 2024-10-10 에이씨 이뮨 에스에이 항-알파시누클레인 치료 백신
KR20250040007A (ko) * 2022-07-14 2025-03-21 백시니티, 인크. Tau 펩타이드 면역원 작제물
WO2025090817A1 (en) * 2023-10-24 2025-05-01 Janssen Pharmaceuticals, Inc. Tau active functional assays
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1994013795A1 (en) 1992-12-14 1994-06-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
PT1036092E (pt) 1997-12-03 2005-09-30 Biogen Inc Compos~icoes e metodos de proteinas hidrofobicamente modificadas
US6314469B1 (en) 1999-02-26 2001-11-06 I-Dns.Net International Pte Ltd Multi-language domain name service
JP2004503747A (ja) 2000-07-11 2004-02-05 モレキュラー　ジェリアトリクス　コーポレイション 結合物質の同定するための試薬と方法
GB0114719D0 (en) 2001-06-15 2001-08-08 Glaxo Group Ltd Compound
WO2003066649A1 (en) 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
ATE514707T1 (de) 2002-04-19 2011-07-15 Univ Toronto Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
EP1691666B1 (en) 2003-12-12 2012-05-30 University of Washington Catheterscope 3d guidance and interface system
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
EP1879613B1 (en) 2005-05-05 2011-11-30 Merck Sharp & Dohme Corp. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
US7977314B2 (en) 2005-12-02 2011-07-12 Amorfix Life Sciences Limited Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
KR101152557B1 (ko) 2005-12-12 2012-09-07 에이씨 이뮨 에스.에이. 치료 백신
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
CN101965365A (zh) 2007-10-19 2011-02-02 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
CA2739318A1 (en) 2008-08-07 2010-02-11 Mercia Pharma, Llc Immunotherapeutic compositions for the treatment of alzheimer's disease
CN102365295A (zh) 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
HUE055739T2 (hu) 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
AU2010291933B2 (en) 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
CA2796722C (en) 2010-04-19 2021-06-01 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ME03008B (me) 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
US20140314837A1 (en) 2011-09-23 2014-10-23 Ac Immune S. A. Vaccine Therapy
EP2770089B1 (en) 2011-10-21 2025-03-05 Mitsubishi Chemical Corporation Gallium NITRIDE SEMICONDUCTOR CRYSTAL
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US20170368167A9 (en) * 2012-08-21 2017-12-28 The Institute For Molecular Medicine Compositions and methods related to neurological disorders
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
BR112016029579A2 (pt) 2014-06-26 2017-08-22 Janssen Vaccines & Prevention Bv anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
NZ775762A (en) 2015-06-05 2025-02-28 Genentech Inc Anti-tau antibodies and methods of use
BR112017028269A2 (pt) 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
EP3795061B1 (en) 2015-08-14 2025-12-03 Intuitive Surgical Operations, Inc. Systems and methods of registration for image-guided surgery
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
UA128383C2 (uk) 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
CN111787942B (zh) 2017-10-25 2024-03-29 杨森制药公司 磷酸化Tau肽的组合物及其用途
EP3706795A4 (en) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
MY206596A (en) * 2019-02-08 2024-12-25 Janssen Pharmaceuticals Inc Method of safe administration of phosphorylated tau peptide vaccine
JOP20210284A1 (ar) 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو

Similar Documents

Publication Publication Date Title
JP2021501147A5 (enExample)
JP2022529529A5 (enExample)
JP2012520852A5 (enExample)
JP2025163031A5 (enExample)
JP2012522754A5 (enExample)
Martin-Rapun et al. Targeted nanoparticles for the treatment of Alzheimer's disease
CN111787942B (zh) 磷酸化Tau肽的组合物及其用途
US11591377B2 (en) Heterologous administration of tau vaccines
JP2012530055A5 (enExample)
US12324855B2 (en) Method of safe administration of phosphorylated Tau peptide vaccine
JP2014502141A5 (enExample)
AU2020348916B2 (en) Detection of antibodies against RAN proteins from serum and tissue lysates
JP5474807B2 (ja) 改変アミロイドβペプチド
JP2025506472A5 (enExample)
JP2014531455A5 (enExample)
US20250152684A1 (en) Anti-Alpha-Synuclein Therapeutic Vaccines
JP2024534901A5 (enExample)
US20250134973A1 (en) Liposomes Containing Phosphorylated Tau Peptides for Inducing Sustained Immune Responses
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗
HK40105209A (zh) 磷酸化tau肽的组合物及其用途
JP2025041635A5 (enExample)
CN120583938A (zh) 脂质体构建体
HK40039870B (zh) 磷酸化Tau肽的组合物及其用途